Flynn: Eli Lilly could capture a significant part of a $100 billion market with Zepbound.
Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan ...
Investor's Business Daily on MSN34m
How Richard DiMarchi Revolutionized Diabetes Treatment
Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi.